Neoplastic pericardial disease in lung cancer: Impact on outcomes of different treatment strategies. A multicenter study

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 340-347

  Lestuzzi, Chiara ^a   Bearz, Alessandra ^a   Lafaras, Christos ^b   Gralec, Renata ^c   Cervesato, Eugenio ^d   Tomkowski, Witold ^c   DeBiasio, Marzia ^e   Viel, Elda ^a   Bishiniotis, Theodoros ^b   Platogiannis, Dimitrios N ^b   Buonadonna, Angela ^a   Tartuferi, Lucia ^a   Piazza, Rita ^d   Tumolo, Salvatore ^f   Berretta, Massimiliano ^a   Santini, Francesco ^g   Imazio, Massimo ^h  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^d ARC   (Italy)

^e UNIVERSITY HOSPITAL OF UDINE   (Italy)

^f Division of Oncology   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

^h MARIA VITTORIA HOSPITAL   (Italy)

Author keywords

Chemotherapy; Intrapericardial instillation; Lung cancer; Malignant pericardial effusion

Indexed keywords

BLEOMYCIN; CISPLATIN; TENIPOSIDE; THIOTEPA;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART CATHETER; HEART METASTASIS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERICARDITIS; PRIORITY JOURNAL; SCLEROTHERAPY; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CATHETERIZATION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; PERICARDITIS; TREATMENT OUTCOME;

EID: 79955485122     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.013     Document Type: Article

References (49)

1. Olopade O.I., Ultmann J.E. Malignant effusions. CA-A Cancer J Clin 1991, 41:166-179.
2. Celermajer D., Boyer M., Bailey B.P., Tattersall M.H. Pericardiocentesis of symptomatic pericardial effusion: a study of 36 patients. Med J Aust 1991, 154(January):9-22.
3. Lorbar M., Spodick D.H. "Idiopathic" pericarditis-the clinician's challenge (nothing is idiopathic). Int J Clin Pract 2007, 61:138-142.
4. Smith F.E., Lane M., Hudgkins P.T. Conservative management of malignant pericardial effusion. Cancer 1974, 33:47-57.
5. Maruyama R., Yokoyama H., Seto T., Nagashima S., Kashiwabara K., Araki J., et al. Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial. J Thorac Oncol 2007, 2:65-68.
6. Bischiniotis T.S., Lafaras C.T., Platogiannis D.N., Moldovan L., Barbetakis N.G., Katseas G.P. Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. HJC 2005, 46:324-329.
7. Vaitkus P.T., Herrmann H.C., LeWinter M.M. Treatment of malignant pericardial effusion. JAMA 1994, 272:59-64.
8. Okamoto H., Shinkai T., Yamakido M., Saijo N. Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion. Cancer 1993, 71(January (1)):93-98.
9. Tomkowski W.Z., Filipecki S. Intrapericardial cisplatin for the management of patients with large pericardial effusion in the course of lung cancer. Lung Cancer 1997, 16:215-222.
10. 32P-colloid. Br J Cancer 1999, 80(August (12)):1955-1957.
11. Maisch B., Ristic A.D., Pankuweit S., Neubauer A., Moll R. Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 2002, 23:1625-1631.
12. Martinoni A., Cipolla C.M., Cardinale D., Civelli M., Lamantia G., Colleoni M., et al. Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa. Chest 2004, 126:1412-1416.
13. Tomkowski W.Z., Wisniewska J., Szturmowicz M., Kuca P., Burakowski J., Kober J., et al. Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer 2004, 12:53-57.
14. Wilkes J.D., Fidias P., Vaickus L., Perez R.P. Malignancy-related pericardial effusion 127 cases from the Roswell Park Cancer Institute. Cancer 1995, 76:1377-1387.
15. Wang P.C., Yang K.Y., Chao J.Y., Ming Liu J., Perng R.P., Yen S.Hl. Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer. Chest 2000, 118:744-749.
16. Kunitoh H., Tamura T., Shibata T., Imai M., Nishiwaki Y., Nishio M., et al. A randomized trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer. Br J Cancer 2009, 100:464-469.
17. Maisch B., Ristic A.D. Practical aspects of the management of pericardial disease. Heart 2003, 89:1096-1103.
18. LeWinter M.M., Kabbani S. Pericardial diseases. Braunwald's heart disease 2005, 1766-1768. Elsevier Saunders, Philadelphia. 7th ed. D.P. Zopes, P. Libby, R.O. Bonow, E. Braunwald (Eds.).
19. Swanson N., Mirza I., Wijesinghe N., Devlin Gl. Primary percutanoeus ballon pericardiotomy for malignant pericardial effusion. Cathet Cardiovasc Interv 2008, 71:504-507.
20. Liang Q.-L., Shi H.-Z., Quin H.-J., Liang X.-D., Jiang J., Yang H.-B. Diagnostic accuracy of tumor markers for malignant pleural effusion: a meta-analysis. Thorax 2008, 63:35-41.
21. Szturmowicz M., Tomkowski W., Fijialkowska A., Fijialkowska A., Kupis W., Cieslik A., et al. Diagnostic utility of CYFRA 21-1 and CEA assays in opericardal fluid for the recognition of neoplastic pericarditis. Int J Biol Markers 2005, 20:43-49.
22. Lestuzzi C., Biasi S., Nicolosi G.L., Lodeville D., Pavan D., Collazzo R., et al. Secondary neoplastic infiltration of the myocardium diagnosed by two-dimensional echocardiography in seven cases with anatomic confirmation. J Am Coll Cardiol 1987, 9:439-445.
23. Maisch B., Seferovic P.M., Ristic A.D., Erbel R., Rienmüller R., Adler Y., et al. (The taskforce on the diagnosis and management of pericardial diseases of the European Society of Cardiology). Guidelines on the diagnosis and management of pericardial diseases. Eur Heart J 2004, 1:1-28.
24. Tsang T.S.M., Freeman W.K., Sinak L.J., Seward J.B. Echocardiographically guided pericardiocentesis: evolution and state-of-the-art technique. Mayo Clin Proc 1998, 73:647-652.
25. Mermel L.A. Prevention of intravascular catheter-related infections. Ann Intern Med 2000, 132:391-402.
26. Therasse P. Evaluation of response: new and standard criteria. Ann Oncol Med 2002, 127-129.
27. Cademartiri F., Luccichenti G., Maffei E., Fusaro M., Palumbo A., Soliani P., et al. Imaging for oncologic staging and follow-up: review of current methods and novel approaches. Acta Biomed 2008, 79:85-91.
28. Kaplan E.L., Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958, 53:457-481.
29. Cox D.R. Regression models and life-tables. J R Stat Soc (B) 1972, 34:187-220.
30. Tamura A., Matsubara O., Yoshimura N., Kasuga T., Akagawa S., Aoki N. Cardiac metastasis of lung cancer. A study of metastatic pathways and clinical manifestations. Cancer 1992, 70:437-442.
31. Figoli F., Zanette M.L., Tirelli U., Sorio R., Lestuzzi C., Urso R., et al. Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion. Cancer Chemother Pharmacol 1987, 20:239-242.
32. Lerner-Tung M.B., Chang A.Y.C., Ong L.S., Kreiser D. Pharmacokinetics of intrapericardial administration of 5-fluorouracil. Cancer Chemother Pharmacol 1997, 40:318-320.
33. Moriya T., Takiguchi Y., Tabeta H., Watanabe R., Kimura H., Nagao K., et al. Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. Br J Cancer 2000, 83:858-862.
34. Casper E.S., Kelsen D.P., Alcock N.W., Lewis J.L. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the Iv route. Cancer Treat Rep 1983, 67:235-238.
35. Liu J., Meisner D., Kwong E., Wu X.Y., Johnston M.R. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable paclitaxel colloids controls lymphatic metastasis in lung cancer. Cancer Res 2009, 69:1174-1178.
36. Tomkowski W., Szturmowicz M., Fijalkowska A., Burakowski J., Filipecki S. New approaches to the management and treatment of malignant pericardial effusion. Support Care Cancer 1997, 5:64-66.
37. Janne P.A., Freidlin B., Saxman S., Johnson D.H., Livingston R.B., Shepherd F.A., et al. Twenty-five years of clinical research for patients with limited stage small cell lung carcinoma in North America. Cancer 2002, 95:1528-1538.
38. Kunitoh H., Tamura T., Saijo N. Reply to 'Malignant pericardial effusion: sclerotherapy or local chemotherapy?'. Br J Cancer 2009, 101:736-737.
39. Lestuzzi C., Bearz A., Lafaras C., Gralec R., Viel E., Buonadonna A., et al. Malignant pericardial effusion: sclerotherapy or local chemotherapy?. Br J Cancer 2009, 101:734-735.
40. Gatenby R.A. A change of strategy in the war of cancer. Nature 2009, 459:508-509.
41. Sorensen M., Felip E. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl. 2):ii41-ii42.
42. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl. 2):ii39-ii40.
43. Elias D., Lefevre G.H., Chevalier G., Brouquet A., Marchal F., Classe J.M., et al. Complete cytoreductive surgery plus intraperitoneal chemohypertermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009, 27:681-685.
44. Liu G., Crump M., Goss P.E., Dancey J., Shepherd F.A. Prospective comparison of the sclerosing agents doxycicline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol 1996, 14:3141-3147.
45. Spodick D.H. Acute cardiac tamponade. N Engl J Med 2003, 349-390.
46. Mercé J., Sagristà-Sauleda J., Permanyer-Miralda G., EvangelistaSoler-Soler J. Correlation between clinical and Doppler echocardiographic findings in patients with moderate and large pericardial effusion: implications for the diagnosis of cardiac tamponade. Am Heart J 1999, 138:759-764.
47. Troughton R.W., Asher C.R., Klein A.L. Pericarditis. Lancet 2004, 363:717-727.
48. Edoute Y., Malberger E., Kuten A. Symptomatic pericardial effusion in lung cancer patients: the role of fluid cytology. J Surg Oncol 1990, 45:121-123.
49. Gornik H.L., Gerhand-Herman M., Beckman J.A. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 2005, 23:5211-5216.